Literature DB >> 17517595

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.

Andreas Muhs1, David T Hickman, Maria Pihlgren, Nathalie Chuard, Valérie Giriens, Carine Meerschman, Ingrid van der Auwera, Fred van Leuven, Masae Sugawara, Marie-Catherine Weingertner, Burkhard Bechinger, Ruth Greferath, Nadine Kolonko, Luitgard Nagel-Steger, Detlev Riesner, Roscoe O Brady, Andrea Pfeifer, Claude Nicolau.   

Abstract

We investigated the therapeutic effects of two different versions of Abeta(1-15 (16)) liposome-based vaccines. Inoculation of APP-V717IxPS-1 (APPxPS-1) double-transgenic mice with tetra-palmitoylated amyloid 1-15 peptide (palmAbeta(1-15)), or with amyloid 1-16 peptide (PEG-Abeta(1-16)) linked to a polyethyleneglycol spacer at each end, and embedded within a liposome membrane, elicited fast immune responses with identical binding epitopes. PalmAbeta(1-15) liposomal vaccine elicited an immune response that restored the memory defect of the mice, whereas that of PEG-Abeta(1-16) had no such effect. Immunoglobulins that were generated were predominantly of the IgG class with palmAbeta(1-15), whereas those elicited by PEG-Abeta(1-16) were primarily of the IgM class. The IgG subclasses of the antibodies generated by both vaccines were mostly IgG2b indicating noninflammatory Th2 isotype. CD and NMR revealed predominantly beta-sheet conformation of palmAbeta(1-15) and random coil of PEG-Abeta(1-16). We conclude that the association with liposomes induced a variation of the immunogenic structures and thereby different immunogenicities. This finding supports the hypothesis that Alzheimer's disease is a "conformational" disease, implying that antibodies against amyloid sequences in the beta-sheet conformation are preferred as potential therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517595      PMCID: PMC1887581          DOI: 10.1073/pnas.0703137104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.

Authors:  C Soto
Journal:  Mol Med Today       Date:  1999-08

2.  A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR.

Authors:  Aneta T Petkova; Yoshitaka Ishii; John J Balbach; Oleg N Antzutkin; Richard D Leapman; Frank Delaglio; Robert Tycko
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-12       Impact factor: 11.205

3.  Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Authors:  H L Weiner; C A Lemere; R Maron; E T Spooner; T J Grenfell; C Mori; S Issazadeh; W W Hancock; D J Selkoe
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

4.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

5.  A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice.

Authors:  Claude Nicolau; Ruth Greferath; Teodor Silviu Balaban; Jaime E Lazarte; Robert J Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

6.  Evidence of secondary structure by high-resolution magic angle spinning NMR spectroscopy of a bioactive peptide bound to different solid supports.

Authors:  J Furrer; M Piotto; M Bourdonneau; D Limal; G Guichard; K Elbayed; J Raya; J P Briand; A Bianco
Journal:  J Am Chem Soc       Date:  2001-05-09       Impact factor: 15.419

7.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

8.  Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.

Authors:  A Monsonego; R Maron; V Zota; D J Selkoe; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

9.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

Authors:  Jean-Cosme Dodart; Kelly R Bales; Kimberley S Gannon; Stephen J Greene; Ronald B DeMattos; Chantal Mathis; Cynthia A DeLong; Su Wu; Xin Wu; David M Holtzman; Steven M Paul
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

Review 10.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

View more
  64 in total

1.  Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.

Authors:  Nelly Joseph-Mathurin; Olène Dorieux; Stéphanie G Trouche; Allal Boutajangout; Audrey Kraska; Pascaline Fontès; Jean-Michel Verdier; Einar M Sigurdsson; Nadine Mestre-Francés; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2013-06-22       Impact factor: 4.673

2.  Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases.

Authors:  David T Hickman; María Pilar López-Deber; Dorin Mlaki Ndao; Alberto B Silva; Deepak Nand; Maria Pihlgren; Valérie Giriens; Rime Madani; Annie St-Pierre; Hristina Karastaneva; Luitgard Nagel-Steger; Dieter Willbold; Detlev Riesner; Claude Nicolau; Marc Baldus; Andrea Pfeifer; Andreas Muhs
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 3.  Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Authors:  David H Cribbs
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 4.  Immunotherapy for tauopathies.

Authors:  Jiaping Gu; Einar M Sigurdsson
Journal:  J Mol Neurosci       Date:  2011-07-08       Impact factor: 3.444

Review 5.  Improving Memory and Cognition in Individuals with Down Syndrome.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 6.  Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines.

Authors:  Hayk Davtyan; Andrew Bacon; Irina Petrushina; Karen Zagorski; David H Cribbs; Anahit Ghochikyan; Michael G Agadjanyan
Journal:  Hum Vaccin Immunother       Date:  2014-02-13       Impact factor: 3.452

Review 7.  CD4 T cells in immunity and immunotherapy of Alzheimer's disease.

Authors:  Alon Monsonego; Anna Nemirovsky; Idan Harpaz
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 8.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 9.  Developing therapeutic vaccines against Alzheimer's disease.

Authors:  Thomas Wisniewski; Eleanor Drummond
Journal:  Expert Rev Vaccines       Date:  2015-12-11       Impact factor: 5.217

Review 10.  Recent Progress in the Pharmacotherapy of Alzheimer's Disease.

Authors:  Rita Khoury; Kush Patel; Jake Gold; Stephanie Hinds; George T Grossberg
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.